Drug firm Cipla Ltd on Thursday (October 23) said the company and Eli Lilly and Company (India) Private Ltd (Lilly) have entered into an agreement for the distribution and promotion of tirzepatide in India under a new brand name, Yurpeak.

Under this strategic arrangement, Cipla will distribute and promote Yurpeak, marking the second brand of tirzepatide to be launched in the country. Lilly, which introduced tirzepatide in India in March 2025 under the brand name Mounjaro, will continue to manufacture and supply the drug to Cipla. The pricing for Yurpeak will remain the same as Mounjaro.

Winselow Tucker, President and General Manager, Lilly India, said, "The introduction of a second brand of tirzepatide in India through our commercial agreement with Cipla furthers Lilly’s commitment t

See Full Page